Clinical Edge Journal Scan

Adults with moderate-to-severe AD are prone to renal malignancy


 

Key clinical point: Adults with moderate-to-severe atopic dermatitis (AD) are at a significantly higher risk for renal malignancy, with the risk for overall malignancy being higher in adults with AD regardless of the disease severity.

Major finding: Compared with adults without AD, those with moderate-to-severe AD had a significantly increased risk for renal malignancy (adjusted hazard ratio [aHR] 1.533; 95% CI 1.209-1.944); moreover, the risk for overall malignancy was higher in adults with mild (aHR 1.061; 95% CI 1.006-1.118) and moderate-to-severe (aHR 1.061; 95% CI 1.014-1.110) AD.

Study details: Findings are from a population-based cohort study including 22,430 adults with mild AD, 34,187 adults with moderate-to-severe AD, and 3,810,530 adults without AD.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Oh J et al. Increased risk of renal malignancy in patients with moderate to severe atopic dermatitis. Cancers (Basel). 2023;15(20):5007 (Oct 16). doi: 10.3390/cancers15205007

Recommended Reading

Review estimates acne risk with JAK inhibitor therapy
MDedge Dermatology
AAD updates guidelines for managing AD with phototherapy and systemic therapies
MDedge Dermatology
Lebrikizumab rapidly relieves itch and itch-associated sleep loss in AD
MDedge Dermatology
Upadacitinib is effective and well-tolerated in difficult-to-treat atopic dermatitis
MDedge Dermatology
Real-world efficacy and safety of dupilumab in children with atopic dermatitis age < 12 years
MDedge Dermatology
Study shows bidirectional association between alopecia areata and atopic dermatitis
MDedge Dermatology
Lebrikizumab compared with dupilumab leads to equal or superior long-term outcomes in AD
MDedge Dermatology
Children with atopic dermatitis have a higher risk for multiple comorbidities
MDedge Dermatology
Atopic dermatitis is a potential risk factor for cognitive dysfunction in middle-aged and older adults
MDedge Dermatology
Meta-analysis evaluates the comparative efficacy of systemic immunomodulators against AD
MDedge Dermatology